Literature DB >> 20613720

Clinical trial simulation: a review.

N Holford1, S C Ma, B A Ploeger.   

Abstract

Modeling and simulation in general, and specifically clinical trial simulation (CTS), have been recognized by the (larger) pharmaceutical companies and regulatory authorities as being pivotal to improving the efficiency of the drug development process. This includes the use of CTS to learn about drug effectiveness and safety and to optimize trial designs at the various stages of development. By reviewing papers published during the period January 2000-January 2010, this paper discusses recent developments with respect to methodology, applications, and lessons learned in the use of CTS in the development and clinical use of specific drugs. It is expected that future CTS experiments will be aided by the hybridization of optimal design methods with computationally intensive stochastic simulations. This will take advantage of optimizing the experimental design and leave the task of evaluating the probable real-world performance of a limited number of candidate trial designs and analysis procedures.

Entities:  

Mesh:

Year:  2010        PMID: 20613720     DOI: 10.1038/clpt.2010.114

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  51 in total

1.  Population pharmacokinetics of lamotrigine in Indian epileptic patients.

Authors:  Surulivelrajan Mallaysamy; Martin G Johnson; Padma G M Rao; Thiyagu Rajakannan; Lokesh Bathala; Karthik Arumugam; Johan G C van Hasselt; Devarakonda Ramakrishna
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 3.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

Review 4.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

6.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Authors:  Giulia Lestini; Cyrielle Dumont; France Mentré
Journal:  Pharm Res       Date:  2015-06-30       Impact factor: 4.200

Review 7.  Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

8.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

9.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 10.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.